Anti-tumour necrosis factor agents and lipid profile: a class effect?

Garcês, Sandra; Santos, María José; Vinagre, Filipe; Roque, Rafael; Silva, J A C da

doi:10.1136/ard.2007.078287

Cited by 35 publications

(26 citation statements)

References 8 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1,2,5] Garces et al have reported a lower atherogenic lipid profile in etanercept-treated patients than in infliximab-treated patients. [7] These authors reported that after 1 year of treatment with etanercept, there was a significant increase in HDL and no significant changes in total cholesterol or LDL levels. Furthermore, improvement in TG levels was observed after etanercept use.…”

Section: Etanercept-induced Hypertriglyceridemia During the Treatmentmentioning

confidence: 96%

“…Furthermore, improvement in TG levels was observed after etanercept use. [7] The different effect on lipid profile of etanercept and other anti-TNF-α were proposed to be related to an additional blockage of lymphotoxin-α mediated by etanercept, leading to a less pro-atherogenic profile. [7] Nevertheless, our patient developed an HTG following treatment with this drug.…”

Section: Etanercept-induced Hypertriglyceridemia During the Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis

González‐López

Blanco

García-Ibarbia

et al. 2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Section: Etanercept-induced Hypertriglyceridemia During the Treatmentmentioning

confidence: 96%

Section: Etanercept-induced Hypertriglyceridemia During the Treatmentmentioning

confidence: 99%

Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis

González‐López

Blanco

García-Ibarbia

et al. 2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

“…These results suggest that long-term therapy with infliximab may be pro-atherogenic. This may, however, not be the case for other TNF antagonists 53,67,68 . Apart from these metabolic effects and the effect on the surrogate markers of atherosclerosis, anti-TNF treatment also seems to have an influence on clinical outcome.…”

Section: Other Biologicalsmentioning

confidence: 96%

“…In various studies, all three available TNF antagonists have been shown to improve insulin resistance [61][62][63][64][65] . Results of short-term studies on the effects of biologic agents regarding dyslipidaemia are very inconsistent, with varying results using different TNF antagonists 53,64,[66][67][68] . The short-term effects of infliximab on the lipid profile at first seemed favourable.…”

Section: Other Biologicalsmentioning

confidence: 99%

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview

et al. 2014

View full text Add to dashboard Cite

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the eff ects of diff erent RA therapies (methotrexate, TNF antagonists and other biologicals).

show abstract

“…Ультразвуковой мониторинг КИМ поз-воляет оценивать влияние течения заболевания, традици-онных факторов риска и лекарственных препаратов. Нес-колькими пилотными исследованиями показана инвер-сия ЭД и КИМ на фоне лечения генно-инженерными биологическими препаратами (ГИБП) [14][15][16][17][18], несмотря на усугубление дислипидемии, которая, возможно, явля-ется класс-зависимым эффектом [19].…”

unclassified

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis

Волков¹,

Волков²,

Lineva³

et al. 2010

rsp

View full text Add to dashboard Cite

Эндотелиальная дисфункция играет ключевую роль в патогенезе атеросклероза. Увеличение риска развития сердечно-сосуди-стых заболеваний у больных ревматоидным артритом (РА) свидетельствует о значении воспаления в возникновении и прогрес-сировании атеросклероза. Ритуксимаб (РТМ, моноклональные антитела к CD20-позитивным B-лимфоцитам) применяется для лечения пациентов с активным РА.Цель. Оценить влияние РТМ на эндотелиальную функцию у пациентов с активным РА. Материал и методы. В исследование было включено 20 пациентов с активным РА (DAS 28>5,0), средний возраст 50 (41,5; 63) лет, средняя длительность заболевания 95,7 (24; 144) (r=-0,44, p=0,049), длительностью заболевания (r=0,6, p=0,017), уровнем холестерина (r=0,48, p=0,045), толщиной комплек-са интима-медиа общих сонных артерий (r=0,52, p=0,023), а также наличием кардиоваскулярных факторов риска (r=0,51, p=0,027). После проведения курса лечения РТМ не было выявлено статистически значимых различий ПЗВД между исходным значением и на 8, 16, 24-й неделях (12,8±5,7; 11,3±5,2; 14,3±7,1; 12,5±5,2% соответственно (r=-0.44; p=0.049), disease duration (r = 0.6; p=0.017), cholesterol level (r=0.48; p=0.045), common carotid artery intima-media thickness (r=0.52; p=0.023), and cardiovascular risk factors (r=0.51; p=0.027). No statistically significant differences were found in the baseline value of FDVD and those observed after a course of RTM therapy and at weeks 8, 16, 24 (12.8±5.7, 11.3±5.2, 14.3±7.1, and 12.5±5.2%, respectively). All the patients were

show abstract

Anti-tumour necrosis factor agents and lipid profile: a class effect?

Cited by 35 publications

References 8 publications

Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis

Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview

Impact of rituximab therapy on endothelial function and other markers of atherosclerosisin patients with active rheumatoid arthritis

Contact Info

Product

Resources

About